FDA has approved asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma

Share This Post

August 2021: The Food and Drug Administration has approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as part of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adults and children aged one month and up who have developed hypersensitivity to E. coli-derived as

The efficacy of JZP458-201 (NCT04145531), an open-label, multi-cohort, multicenter trial in 102 patients with ALL or LBL who had hypersensitivity to E. coli-derived asparaginase as part of a multi-agent chemotherapy regimen, was examined. The average age was ten years, with a range of one to twenty-four years. Rylaze was administered intramuscularly in varied dosages to the patients.

You may like to read : Cancer treatment in India

The achievement and maintenance of nadir serum asparaginase activity (NSAA) above the level of 0.1 U/mL was the primary effectiveness outcome measure. Modeling and simulations revealed that with a dosage of 25 mg/m2 injected intramuscularly every 48 hours, 93.6 percent of patients maintained an NSAA of less than 0.1 U/mL 48 hours following a dose of Rylaze (95 percent CI: 92.6 percent , 94.6 percent ).

Abnormal liver tests, nausea, musculoskeletal pain, exhaustion, infection, headache, pyrexia, drug hypersensitivity, febrile neutropenia, decreased appetite, stomatitis, bleeding, and hyperglycemia were the most prevalent side effects (incidence > 20%).

The suggested dosage of Rylaze when replacing a long-acting asparaginase product is 25 mg/m2 taken intramuscularly every 48 hours for the needed length of asparaginase activity.

 

Reference: https://www.fda.gov/

Check details here.

 

Take second opinion on leukemia treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy